Liste des publications GINECO - Cancer Ovaire 2018

SOLO1 – Article (The New England Journal of Medicine)
K. Moore
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
The New England Journal of Medicine - Octobre 2018 (réf. PubMed : PMID: 30345884 - DOI: 10.1056/NEJMoa1810858)
SOLO 2 – Article (Lancet Oncology)
M. Friedlander
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Lancet Oncology - Août 2018 (réf. PubMed : PMID: 30026002 - DOI: 10.1016/S1470-2045(18)30343-7)
EXPRESSION IV – Article (Bulletin du cancer)
M. Lorcet
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
Bulletin du cancer - Août 2018 (réf. PubMed : PMID: 29544693 - DOI: 10.1016/j.bulcan.2018.01.015)
AGO-OVAR 16 – Article (Annals of Oncology)
M. Friedlander
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Annals of Oncology - Mars 2018 (réf. PubMed : PMID: 29267856 - DOI: 10.1093/annonc/mdx796)
TMRG – Article (Bulletin du cancer)
C. Rousset-Jablonski
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
Bulletin du cancer - Mars 2018 (réf. PubMed : PMID: 29397916 - DOI: 10.1016/j.bulcan.2017.10.032)

Haut de page

Modifié le 24-07-2019 10:34:27